SelSym Biotech


SelSym Biotech is dedicated to developing innovative therapeutics to address critical clinical needs in hemorrhage control, surgical bleeding, and wound healing. Their mission is to transform patient care and outcomes through advanced technologies like their Hemostatic Healing Hydrogels and SymClot, a novel therapy that mimics platelet functions to enhance hemorrhage control and address platelet supply shortages.

SelSym Biotech

SelSym Biotech


What We Do

SymClot is a synthetic platelet technology that mimics key functions of native platelets in hemostasis and wound healing. It targets wound sites specifically and induces clot retraction, reducing blood loss and improving wound healing outcomes. SymClot is designed for safety, functionality, and ease of storage, providing a reliable supply of hemostatic therapeutics.

SelSym Biotech’s Hemostatic Healing Hydrogels (H3) are designed to address a wide range of clinical needs in bleeding management and wound healing, including hemorrhage control, drug delivery, infection control, and long-term healing support for chronic wounds.


Regenerative Medicine


Key People

Co-Founder | CEO

LinkedIn

Chief Scientific Officer

LinkedIn

Co-Founder | President

LinkedIn

Co-Founder | Senior Scientific Advisor

LinkedIn

Co-Founder | Senior Scientific Advisor

LinkedIn